Weekending:- 10-01-2020 Legal Publication Date:- 03-03 ...ipo.gov.pk/system/files/2200303.pdf · Dr. Attya Bhatti, Dr. Peter John, Shahbaz Ahmad, Dr. Sofia Javed and Dr. Zeerak Asher

Electronic Publication of Patents Journal

under The Patents (Amendments) Act, 2016

Weekending:- 10-01-2020

Legal Publication Date:- 03-03-2020

Journal Code (200303)

Patents’ journal 03-03-2020

1

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents

Ordinance 2000.

06/01/2020

7/2020

Faisal Sheraz Shah, Dr. Attya Bhatti, Dr. Peter John, and Shahbaz Ahmad, Pakistan.

“Architecting Highly Transparent Nano-

coatings”

8/2020

Faisal Sheraz Shah, Dr. Attya Bhatti, Dr. Peter John, Shahbaz Ahmad, Dr. Sofia Javed and Dr. Zeerak Asher Samuel. Pakistan.

“Anti-fog and Anti-microbial coating of Glass Substrate”

9/2020

Shahbaz Ahmad, Dr. Peter John, Dr. Attya Bhatti and Faisal Sheraz Shah. Pakistan.

“Transparent / Clear Coating of Nano-materials on Glass Substrate ”

10/2020

Shahbaz Ahmad, Dr. Peter John, Dr. Attya Bhatti and Faisal Sheraz Shah. Pakistan.

“Using Zno/TiO2 Nanocomposite as Anti-fog and Anti-bacterial Coating for Glass Substrate”

11/2020

Shahbaz Ahmad, Dr. Peter John, Dr. Attya Bhatti, Faisal Sheraz Shah, Dr. Sofia Javed and Dr Zeerak Asher Samuel. Pakistan.

“Zno based Anti-fog and Anti-bacterial Nano-coating for Glass Substrate”

07/01/2020


2

12/2020

PIVOT BIO, INC. U.S.A.

(Priority 07/01/2019 US)

“PLANT COLONIZATION ASSAYS USING NATURAL MICROBIAL BARCODES”

13/2020

PFIZER INC., U.S.A.


“PHARMACEUTICALLY ACCEPTABLE SALT OF 6-CARBOXYLIC ACID OF BENZIMIDAZOLE AND PHARMACEUTICAL COMPOSITION THEREOF

14/2020

Abdul Wasay Rao. Pakistan.

“DRAPRY”

08/01/2020

15/2020

Le Wei, China.

“HOOK NEEDLE FOR HOOK OPERATION OF TRADITIONAL CHINESE MEDICINE WITH FUNCTION OF PERPENDICULAR INSERTION”

16/2020

ALDER BIOPHARMACEUTICALS, INC. U.S.A.

“ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES”

17/2020

ALDER BIOPHARMACEUTICALS, INC. U.S.A.

“TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES”

18/2020

University of Karachi, Pakistan.

“EFFECT OF PAMIDRONATE AND TEMOZOLAMIDE ON MDA-MB-468 CELL LINE”

19/2020

Kanza Naseer and Dr. Imran Hashmi, Pakistan.

“Bacillus sp. removal efficiency”

20/2020


“Bacillus zhangzhouensis removal efficiency”

21/2020


“Staphylococcus gallinarum removal efficiency”


3

22/2020


“Acinetobacter vivianii removal efficiency”

23/2020


“Pseudomonas mandocina removal efficiency”

24/2020

Kanza Naseer and Dr. Imran Hashmi, Pakistan

“Glutamicibacter sp. removal efficiency”

25/2020


“Removal efficiency of Pseudomonas alcaliphila”

26/2020


“Bacillus haynesii removal efficiency”

27/2020


“Pseudomonas sp. removal efficiency”

28/2020


“Bacillus paranthracis removal efficiency”

29/2020


“Bacillus stratosphericus removal efficiency”

30/2020

Irfan Ullah and Office of Research, Innovation and Commercialization (ORIC), University of Management and Technology. Pakistan.

“Centered-Receiver Parabolic Trough Concentrator”

31/2020

SAJID MAHMOOD. Pakistan.

“TOXIC CHIMNEY EMISSION REDUCTION DEVICE FOR ALL BRICK KILNS TECHNOLOGIES AND STEEL INDUSTRIES”

09/01/2020


4

32/2020

Dr. Tariq Javid, Department of Biomedical Engineering,; Mr. Salman Shah, Department of Computing,; Prof. Dr. Tasir Ahmed Mumtaz, Department of Radiology, and Prof. Dr. Muhammad Abid, Department of Mechanical Engineering, Pakistan.

“Fuzzy Contrast Enhancement System with Multiple Transform Domain Operation and Data Fusion”

33/2020

Mr. Raheel Abbas, and Dr. Muhammad Nadeem, Pakistan.

“Dual Functional additive manufacturing device comprising filament making unit and fused deposition modeling (FDM) 3D printer with collar bearings slide system”

10/01/2020

34/2020

ALAR PHARMACEUTICALS INC. Taiwan.


“KETAMINE PAMOATE AND USE THEREOF”


5

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the

applications referred to below at any time within four months from the date of this Patents’

journal may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules

18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on

acceptance of the complete specification under which the specification will be printed and

subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification

index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the

Patent Office on payment of the prescribed charges which may be as certained on application to

the office.

222/2011

High Sealed and Coupled "HSC" FZCO.

UAE.

“A pipe joint”

F16L15/00.

143410

The invention relates to a screw-

threaded pipe joint comprising a pin(20) having at

one end a male screw-threaded portion and a

box(10) having at one end a female portion

having a complementary screw-thread. The pin

and box inter engage along the threaded portions

with the male thread extending to a male stop

shoulder adjacent a complementary stop shoulder

on the olher portion.

The complementary stop shoulder comprises a

recess in the form of a cone receiver having a

radial surface(23) adjacent a corresponding radial

surface(15) on the complementary stop shoulder.

A curved sealing surface(24) on the pin(20)

sealingly engages a corresponding curved scaling

surface(16) on the complementary stop shoulder

of the box(10), each curved sealing surface(16,24)

lying on the are of the circumference of a separate

circle, and wherein the curvature of the box

sealing surface(16) is greater than on the sealing


6

surface(24) on the pin(20).

164/2012

BAYER PHARMA AKTIENGESELLSCHAFT. Germany.

“Branched 3-phenylpropionic acid compound” C07C233/55, A61K31/195 & A61P 9/00.

143411

The present application relates to novel 3-

phenylpropionic acid compound of the formula (I)

which carry a branched or cyclic alkyl substituent

in the 3-position, to processes for their

preparation, to their use for the treatment and/or

prevention of diseases and to their use for

preparing medicaments for the treatment and/or

prevention of diseases, in particular for the

treatment and/or prevention of cardiovascular


7

diseases.

61/2013

Regeneron Pharmaceuticals, Inc. U.S.A.

“ANTI-ASIC1 ANTIBODY AND PHARMACEUTICAL COMPOSITION THEREOF” C07K16/18,C07K16/28 & A61K39/395

143412

The present invention provides an antibody and

antigen-binding fragment thereof that specifically

bind to cells expressing acid-sensing ion channel-

1 (ASIC1). The antibody of present invention

inhibits acid-induced, ASIC1 -mediated ion

currents in cells expressing human ASIC1 and is

useful for the treatment of pain, including pain

associated with surgical intervention and various

diseases and disorders.

196/2013

SANOFI. France.

“THIENOPYRIMIDINE COMPOUND” C07D495/04,A61K31/505 & A61P35/00.

143413

The present invention relates to compounds of

formula (I):

wherein R6 is -CONH2 or a -C(Rα)(Rβ)(OH)

group; R is a substituted phenyl or heteroaryl

group; R7 is an optionally substituted aryl or

heteroaryl group.

Process for the preparation thereof and therapeutic

use thereof.


8

234/2014

DOW AGROSCIENCES LLC, U.S.A.

“HERBICIDAL 4-AMINO-6-(HETEROCYCLIC)PICOLINATE AND 6-AMINO -2-(HETEROCYCLIC)PYRIMIDINE-4-CARBOXYLATE COMPOUND”

A01N43/80, A01N55/00 & C07D401/04.

143414

The present invention relates to herbicidal

compound of the Formula (I):

wherein

X, N, R1, R2, R3, R4, A, and N as defined herein.

67/2015

LES LABORATOIRES SERVIER. France.

I “soquinoline compounds, process of preparation and pharmaceutical composition thereof” C07D217/02, C07D217/24, C07D405/06, A61K 31/472 & A61P9/00.

143415

The present invention relates to a compound of

formula (I):


9

wherein the substituents are as defined in the

claims of the specification.

The present invention further provides a

pharmaceutical composition comprising a

compound of formula (I) and at least one

pharmaceutically acceptable carrier which is

effective in the treatment of systemic arterial

hypertension, pulmonary arterial hypertension,

angina, myocardial infarction, post-angioplasty

restenosis, aortic aneurysm, occlusion of the

peripheral arteries, atherosclerosis, cardiac

fibrosis, heart failure, glaucoma, pathologies of

the cornea, erectile dysfunction, broncho-

obstructive pulmonary diseases, post-radiation

intestinal fibrosis, cutaneous systemic sclerosis,

pulmonary fibrosis associated with pulmonary

arterial hypertension, hepatic diseases, renal

fibrosis and glornerulo-sclerosis, diabetes,

hyperglycaemia, insulin resistance, diabetic

nephropathies induced or not induced by

hypertension, thrombotic diseases, cerebral

vasospasm and resulting cerebral ischaemia.

361/2015

PFIZER INC. U.S.A.

“SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF”

C07D401/06,C07D401/14,C07D405/14, A61K31/47 & A61P35/00.

143416


10

The present invention relates to a compound of

general formula (I)

Wherein R

1, R

2, R

3, R

4, L, X and Z are as defined

in the claims of the specification.

The present invention further provides a

pharmaceutical composition comprising the

claimed compound and a pharmaceutically

acceptable carrier or excipient which is useful for

the treatment of abnormal cell growth in cancer.

123/2016

Evonik Degussa Gmbh. and Evonik Specialty Chemicals (Shanghai) Co., Ltd., Germany.

“Original Equipment Manufacturer (OEM) Textile Finishing Composition comprising of crosslinked aminosiloxanes”

D06M101/32, D06M15/643 & C08G77/38.

143417

Crosslinked aminosiloxanes obtainable by

reaction of identical or different aminosiloxanes

with identical or different epoxide components

which are water-soluble hydrocarbons, the

hydrocarbons comprising oxygen as well as

carbon, and optionally further elements selected

from nitrogen, sulphur and phosphorus, the

hydrocarbon having on average more than one

terminal epoxy group, the epoxy group being a

carbooxirane radical, and, further, not more than

50% of all the amino groups having undergone

reaction with an epoxide group. 428/2016

HONDA MOTOR CO., LTD. Japan.

“INSTRUMENT PANEL STRUCTURE” B60K35/00.

143418


11

Provided is an instrument panel structure that

does not require a lid, allows a fuse box to be

directly accessed, and enables the maintenance of

the fuse box to be more easily performed. The

instrument panel structure includes an upper

instrument panel 1 and a lower instrument panel 2

that cover surroundings of a steering wheel H of a

vehicle and a fuse box 3 that is arranged forward

of the lower instrument panel 2 in the vehicle. A

low end portion 2a of the lower instrument panel

2 is positioned below a lower end of the fuse box

3 and has an opening portion 4 through which the

fuse box 3 is visible. The opening portion 4 is

defined by a first inner surface 5 and a second

inner surface 6 curving downward and forward

from the low end portion 2a of the lower

instrument panel 2 in the vehicle so as to cover

visible inside areas of the lower instrument panel

2.

479/2016

SANOFI. France.

“PHARMACEUTICALLY ACCEPTABLE SALT OF A THIENOPYRIMIDINE COMPOUND”

143419

The present invention relates to a

pharmaceutically acceptable salt of a compound

of formula (I):


12

wherein R6 is -CONH2 or a -C(Rα)(Rβ)(OH)

group; R is a substituted phenyl or heteroaryl

group; R7 is an optionally substituted aryl or

heteroaryl group.

173/2017

HONDA MOTOR CO., LTD. Japan.

“MOTOR CYCLE COMPRISING A DOWN FRAME WHICH EXTENDS DOWNWARD FROM A HEAD PIPE”

B62K11/08.

143420

The invention provides a motor cycle which can

reduce a man hour for assembling an engine in a

down frame. A motor cycle (1) is provided with a

down frame (7) which extends downward from a

head pipe (3), and an engine (5). The down frame

(7) is formed into a hollow shape by bonding a

plate-like member in its end portions. Left and

right side walls extend downward and form left

and right extension portions (44, 45) in a lower

end portion of the down frame (7). A

reinforcement plate (46) is bonded to an inner side

of the left and right extension portions (44, 45).

An engine (5) is supported its front portion by the

extension portions (44, 45).


13

184/2017

PFIZER INC. U.S.A.

“A PHARMACEUTICALLY ACCEPTABLE SALT OF A SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF” C07D401/06, C07D401/14, C07D405/14, A61K31/47 & A61P35/00.

143421

The present invention relates to a

pharmaceutically acceptable salt of a compound

of general formula (I)

Wherein R

1, R

2, R

3, R

4, L, X and Z are as defined

in the claims of the specification. The present

invention further provides a pharmaceutical

composition comprising a pharmaceutically

acceptable salt of the claimed compound and a

pharmaceutically acceptable carrier or excipient

which is useful for the treatment of abnormal cell


14

growth in cancer.

263/2017

DR.S.M.HASAN. Pakistan.

“A washing machine for efficient and crease-free washing of tubular or stiff articles such as rugs, floor mats and carpets” D06F39/00.

143422

A washing machine is disclosed in which a

tubular and/or stiff articles such as rugs, floor

mats, car mats and pieces of carpet can be washed

without subjecting such articles to aggressive

mechanical action. In addition, the same can be

washed without creasing. In the proposed

solution, the article to be washed is suspended in

open width form by securing it in the lid of the

main washing compartment. In this state, washing

of the article is done by jetting washing liquor

onto the surface of the article.

264/2017

Dr.S.M.HASAN. Pakistan.

“A washing machine for delicate and efficient washing of a broad range of laundry loads” D 06F39/00.


15

143423

A washing machine is disclosed in which a broad

range of washing loads can be handled without

wasting excessive washing water. The structure is

based on the use of a 'volume altering device'

which is lowered into the main washing

compartment thereby reducing its effective

volume. This provision also facilitates less

aggressive washing action, particularly when low

washing loads are handled.

307/2017

PFIZER INC. U.S.A.

“SUBSTITUTED CARBONUCLEOSIDE COMPOUND USEFUL AS ANTICANCER AGENT” C07D239/42, C07D491/048, C07D487/04, C07D251/18, C07D519/00, C07D239/84, A61K31/53, A61K31/519, A61K31/505 & A61P 35/00.

143424

Compound of the general formula:


16

wherein;

R1, R

2, R

3, R

9, D, G, R

8, Q, V, Y, Z, X, W, N, OH

are as defined therein; composition containing the

compound.

676/2017

CHINA XD ELECTRIC CO., LTD China.

“COUPLING STRUCTURE FOR TAIL PORTION OF VALVE-SIDE BUSHING” H01F27/32.

143425

A coupling structure for a tail portion of a valve-

side bushing is provided, and the coupling

structure includes a tapered shield pipe, a

coupling sleeve and a valve-side bushing. A

holder is provided on an inside of the tapered

shield pipe. A connection plate is provided at a

circumference of one end, configured to be

connected to the tapered shield pipe, of the

coupling sleeve. The coupling sleeve is connected

to the holder located on the inside of the tapered

shield pipe by the connection plate. A valve-side

lead wire is connected to the one end, configured

to be connected to the tapered shield pipe, of the

coupling sleeve by a terminal, and the valve-side

bushing is inserted into another end of the

coupling sleeve. The coupling structure for the tail


17

portion of the valve-side bushing according to the

present application is simpler and facilitates

installation of the valve-side bushing, effectively

simplifies the entire installation and operation

process, saves installation time, has good

economic and social benefits, and makes the

installation of the valve bushing easier and faster.

664/2019

PFIZER INC., U.S.A.

“Substituted Carbonucleoside Salt Useful as Anticancer Agent” C07D239/42,C07D491/048,C07D487/04, C07D251/18, C07D519/00, C07D239/84, A61K31/53, A61K31/519, A61K31/505 & A61P35/00.

143426

Salt of a compound of the general formula:


18

wherein;

R1, R

2, R

3, R

9, D, G, R

8, Q, V, Y, Z, X, W, N, OH

are as defined therein;

composition containing the compound.

782/2019


“N-OXIDE OF 4-AMINO-6-(HETEROCYCLIC) PICOLINATED AND 6-AMINO-2-(HETEROCYCLIC) PYRIMIDINE-4-CARBOXYLATE COMPOUND”

143427

The present invention relates to an N-oxide of 4-

amino-6-(heterocyclic)picolinate and 6-amino-2-

(heterocyctic)pyrimidine-4-carboxylate


wherein



19

784/2019


“AGRICULTURALLY ACCEPTABLE SALT OF 4-AMINO-6-(HETEROCYCLIC)PICOLINATE AND 6-AMINO-2-(HETEROCYCLIC) PYRIMIDINE-4-CARBOXYLATE COMPOUND”

143428

The present invention relates to an agriculturally

acceptable salt of 4-amino-6-

(heterocyclic)picolinate and 6-amino-2-

(heterocyclic)pyrimidine-4-carboxylate


wherein



20

SEALING FEES DUE-

Notice is hereby given that the Patent may now be sealed on the application referred to below if

it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the

fee of Rs.6750/- should be sent to the Controller of Patents and Designs, The Patent Office,

Karachi.

Accepted

No.

Applicant Name Application

No.

143247

Glaxo Group Limited. United Kingdom.

643/2011

143248

Syngenta Participations AG. Switzerland.

162/2013

143249

Muhammad Saadet Khan (Principal Engineer); Dr. Shahzad Alam (Chairman PCSIR). and Miss Phool Shahzadi(scientific Officer). Pakistan.

192/2013

143250

Huntsman Advanced Materials (Switzerland) GmbH. Switzerland.

385/2013

143251

STICHTING I-F PRODUCT COLLABORATION. Netherlands.

390/2013

143252


498/2013

143253

Zhejiang XinNong Chemical Co., Ltd., and Zhejiang University of Technology. China.

512/2013

143254

Shionogi and Co Ltd. and Glaxo Group Limited Japan.

735/2013


21

143255

Novartis AG. Switzerland.

149/2014

143256


172/2014

143257

GlaxoSmithKline Intellectual Property Development Limited. United Kingdom.

245/2014

143258

Dr. Nighat Sultana, PSO; Dr. Zahra Yaqeen, PSO. and Dr. Yaqeenuddin, PMO. Pakistan.

393/2014

143259

SICPA HOLDING SA, Switzerland.

655/2014

143260

Archroma IP GmbH. Switzerland.

803/2014

143261

(1) APOGENIX GMBH and (2) AbbVie Inc. Germany.

232/2015

143262

INDUSTRIE DE NORA S.p.A. Italy.

472/2015

143263

Graphene Platform Corporation. Japan.

562/2015

143264


590/2015

143265

Shionogi and Co., Ltd. and Glaxo Group limited. Japan.

376/2016


22

143266

ELI LILLY AND COMPANY. U.S.A.

3/2017

143267


294/2017

143268

Powerchina Huadong Engineering Corporation Ltd. China.

584/2017

143269

Graphene Platform Corporation. Japan.

56/2018

143270

Bayer Corporation. U.S.A.

28/2000

143271

Abb Vie Inc. U.S.A.

990/2010

143272


93/2011

143273

DOW AGROSCIENCES LLC. U.S.A.

65/2012

143274

LES LABORATOIRES SERVIER. France.

52/2013

143275

BAYER CORPORATION. U.S.A.

155/2014

143276

PROMETIC PHARMA SMT LIMITED, United Kingdom.

221/2014

143277

Rehana Jafri, PSO, Dr. Arfa Yasmin, CSO, Dr. Zahra Yageen, PSO, Dr. Amir Ahmed, SSO, Irshad Ahmed Khan, EO, & Ghulam Mustafa, RA. Pakistan.

233/2014


23

143278

CASALE SA. Switzerland.

596/2014

143279

COMSATS Institute of Information Technology. Pakistan.

641/2014

143280

Starlinger & Co. Gesellschaft m.b.H. Austria.

690/2014

143281

SAINT-GOBAIN PLACO. France.

3/2015

143282

Monsanto Technology LLC. U.S.A.

145/2015

143283


850/2015

143284

HALLIBURTON ENERGY SERVICES, INC., and ENI S.p.A., U.S.A.

456/2016

143285

Groz-Beckert KG, Germany.

624/2017

143286

Eisai R&D Management Co., Ltd. Japan.

94/2011

143287

Vifor (International) AG . Switzerland.

894/2013

143288


698/2010

143289

DyStar Colours Distribution GmbH. Germany.

935/2011

143290


224/2012


24

143291


248/2012

143292

F. Hoffmann-La Roche AG and Siena Biotech S.p.A. Switzerland.

34/2013

143293


40/2013

143294

ELI LILLY AND COMPANY and Deciphera Pharmaceuticals, LLC. U.S.A.

112/2013

143295

Roche Glycart AG. Switzerland.

532/2013

143296

Dr. Kefi Iqbal, Chairman & Head; Dr. Muhammad Usman, CEO and Dr. Muhammad Sleem Qazi, SSO. Pakistan.

813/2013

143297

M/s. Kanzo AG. Pakistan.

87/2014

143298


125/2014

143299

IRM LLC. Bermuda.

151/2014

143300

SICPA HOLDING SA. Switzerland.

297/2014

143301

NUC ELECTRONICS CO., LTD and KIM, Ji Tae. Korea.

453/2014


25

143302

Galapagos NV . Belgium.

560/2014

143303

F. HOFFMANN-LA ROCHE AG. Switzerland.

699/2014

143304

Novartis AG. Switzerland.

833/2014

143305

CHT R. Beitlich GmbH. Germany.

225/2015

143306

ELI LILLY AND COMPANY and Deciphera Pharmaceuticals, LLC. U.S.A.

655/2015

143307


590/2016

143308


591/2016

143309

MERCK SHARP & DOHME CORP. U.S.A.

820/2016


26

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

S. No. Design

No. Title & Class Applicant

06/01/2020

1. 20266 ELAF BOTTLE (CLASS-03) Mr. AMEER HAMZA, M/s. ELAF

FOOD AND BEVERAGES

-sd-

(Dr. Muhammad Fayyaz Ahmad)

Controller of Patents

& Registrar of Designs

Ph: 99230591

Documents

Weekending:- 10-01-2020 Legal Publication Date:- 03-03 ...ipo.gov.pk/system/files/2200303.pdf · Dr. Attya Bhatti, Dr. Peter John, Shahbaz Ahmad, Dr. Sofia Javed and Dr. Zeerak Asher